Breaking News
Get 55% Off 0
Get Premium Data for Cyber Monday: Up to 55% Off InvestingPro
CLAIM SALE
Close

AstraZeneca PLC (A1ZN34)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
69.41 +1.70    +2.51%
06/12 - Closed. Currency in BRL
Type:  Equity
Market:  Brazil
ISIN:  BRA1ZNBDR003 
  • Volume: 6,020
  • Bid/Ask: 68.57 / 70.00
  • Day's Range: 66.81 - 69.41
AstraZeneca 69.41 +1.70 +2.51%

AstraZeneca PLC Company Profile

 
Get an in-depth profile of AstraZeneca PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

89900

Equity Type

DRC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Contact Information

Address 1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge, CB2 0AA
United Kingdom
Phone 44 20 3749 5000
Fax -

Top Executives

Name Age Since Title
Pascal Soriot 62 2012 CEO & Executive Director
Rain Henderson - - Member of External Sustainability Advisory Board
Jeffrey Pott - 2009 CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Pam P. Cheng 52 2015 EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Aradhana Sarin 48 2021 CFO & Executive Director
Michel Demare 68 2019 Independent Chairman
Deborah DiSanzo Eldracher 64 2017 Independent Non-Executive Director
Marcus Wallenberg 68 1999 Non-Executive Director
Sherilyn S. D. McCoy 65 2017 Independent Non-Executive Director
Philip Arthur John Broadley 63 2017 Senior Independent Non-Executive Director
Nazneen Rahman 55 2017 Independent Non-Executive Director
Louise Nicholls - - Member of External Sustainability Advisory Board
Andreas Rummelt 68 2021 Independent Non-Executive Director
Euan A. Ashley 51 2020 Independent Non-Executive Director
Diana Layfield 52 2020 Independent Non-Executive Director
Pankaj Bhatia - - Member of External Sustainability Advisory Board
Polly Courtice 72 - Member of External Sustainability Advisory Board
Anna Olive Magdelene Manz 51 2023 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

A1ZN34 Comments

Write your thoughts about AstraZeneca PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email